Avalyn Pharma Inc., a clinical-stage biopharmaceutical company pioneering inhaled therapies for treating pulmonary fibrosis, is set to begin trading on the Nasdaq Global Select Market under the ticker symbol "AVLN" on April 30, 2026.
The company has priced its upsized initial public offering of 16.67 million shares of its common stock at $18.00 per share. The offering is scheduled to close on May 1, 2026, and gross proceeds to Avalyn are expected to be $300 million.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.